Pharmacokinetics of Total and Unbound Cefazolin during Veno-Arterial Extracorporeal Membrane Oxygenation: A Case Report

Chemotherapy. 2019;64(3):115-118. doi: 10.1159/000502474. Epub 2019 Oct 14.

Abstract

Extra-corporeal membrane oxygenation (ECMO) therapy could affect effective drug concentrations via adsorption onto the oxygenator or associated circuit. We describe a case of a 25-year-old female who required a veno-arterial ECMO therapy for refractory cardiac arrest due to massive pulmonary embolism. She had mild renal dysfunction as a result of the cardiac arrest. A total of 2 g of intravenous cefazolin 8-hourly was administered. Pre- and post-oxygenator blood samples were collected at 0, 1, 4, and 8 h post antibiotic administration. Samples were analyzed for total and unbound cefazolin concentrations. Protein binding was ∼60%. Clearance was reduced due to impaired renal function. The pharmacokinetics of cefazolin appear to not be affected by ECMO therapy and dosing adjustment may not be required.

Keywords: Cefazolin; Extra-corporeal membrane oxygenation; Pharmacokinetics.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Area Under Curve
  • Cefazolin / administration & dosage*
  • Cefazolin / blood
  • Cefazolin / metabolism
  • Extracorporeal Membrane Oxygenation*
  • Female
  • Half-Life
  • Heart Arrest / complications
  • Heart Arrest / diagnosis
  • Humans
  • Protein Binding
  • Pulmonary Embolism / complications
  • Pulmonary Embolism / pathology
  • ROC Curve

Substances

  • Cefazolin